Key Highlights
- Infinimmune teams up with Grid Therapeutics to explore new antibody drugs for non-small cell lung cancer.
- The collaboration will focus on studying antibody responses in a large patient cohort, using Infinimmune’s Anthrobody™ and Complete Human™ technologies.
- Wyatt McDonnell, PhD, CEO of Infinimmune, and Edward (Ned) F. Patz, Jr., MD, CEO of Grid Therapeutics, expressed excitement about this transformative partnership for cancer therapeutics development.
Source: Business Wire
Notable Quotes
- “We are delighted to partner with Grid Therapeutics to study the antibody response in a carefully curated and longitudinal cohort of non-small cell lung cancer patients.” – Wyatt McDonnell, PhD, CEO at Infinimmune
- “We are thrilled to partner with the Infinimmune team in the ongoing and transformative effort to develop novel therapeutic antibodies for cancer patients.” – Edward (Ned) F. Patz, Jr., MD, CEO at Grid Therapeutics
SoH's Take
The partnership between Infinimmune and Grid Therapeutics represents a significant step in cancer treatment innovation. Leveraging Infinimmune’s Anthrobody™ platform and Complete Human™ immunosequencing technology, this collaboration focuses on a patient-centric approach, analyzing detailed antibody responses to identify new therapeutic targets. By combining expertise in human-derived antibodies and a deep understanding of non-small cell lung cancer, this alliance could lead to groundbreaking advancements in immunotherapy, offering hope for more effective and safer treatments for cancer patients. The emphasis on real human immune responses in drug discovery underscores the industry’s shift towards more personalized and biologically relevant therapeutic strategies.
